-+ 0.00%
-+ 0.00%
-+ 0.00%

Is Perrigo (PRGO) Undervalued Following Its Share Price Slide?

Simply Wall St·07/28/2026 15:25:05
Listen to the news

Perrigo (PRGO) has drawn investor attention after recent share performance metrics showed mixed short and longer term returns, prompting fresh questions about how its current US$10.14 price lines up with its fundamentals.

See our latest analysis for Perrigo.

At around US$10.14, Perrigo’s recent share price return over the past month has been slightly positive, although the year to date share price return and 1 year total shareholder return both show steep declines. This suggests momentum has been fading as investors reassess the company’s risk profile and valuation.

If you are reassessing your watchlist after Perrigo’s recent swings, this can be a helpful moment to broaden your search and check out 18 top founder-led companies

Perrigo now trades at a steep discount to both one valuation estimate and the average analyst target, even after its sharp 1 year share price fall. Is that discount generous compensation for risk, or is it a warning that the market’s caution is justified?

Most Popular Narrative: 38.5% Undervalued

Perrigo’s most followed narrative pegs fair value at $16.50, well above the recent $10.14 share price, which puts the focus firmly on execution.

The aging global population and rising consumer interest in self-care and wellness continue to create longer-term demand tailwinds for Perrigo's OTC and nutrition products, providing stable, defensive revenue streams even in periods of macro uncertainty.

Read the complete narrative.

Want to see what stands behind that $16.50 fair value for Perrigo? The narrative leans on steadier revenues, better margins and a richer future earnings multiple. Curious how those moving parts fit together into one valuation story?

Result: Fair Value of $16.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Perrigo narrative can be challenged if weak category demand persists or if infant formula and OTC competition continue to pressure pricing and margins.

Find out about the key risks to this Perrigo narrative.

Next Steps

Given the mix of caution and optimism around Perrigo, this is a good moment to move quickly and check the full picture for yourself. To weigh those concerns against the potential upside, start by reviewing the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Perrigo?

Do not stop with Perrigo. Fresh ideas often come from scanning a wider field, and skipping that step can mean missing opportunities that better fit your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.